Lv2
150 积分 2026-05-13 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
2天前
已完结
Metronomic oral cyclophosphamide & low dose nivolumab for advanced hepatocellular carcinoma (HCC)
16天前
已关闭
Clinical Characteristics and Prognosis of Hepatocellular Carcinoma
1个月前
已完结
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
1个月前
已完结
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
1个月前
已完结
皖公网安备34019202002308
